Navigation Links
Hypertension Vaccine CYT006-AngQb Achieves Strong Blood Pressure,Reduction During Important Early Morning Period When Most Adverse,Cardiovascular Events Occur

m those
presented. There can be no assurance that any other therapeutic entities will enter clinical trials, that clinical trial results will be predictive for
future results, that therapeutic entities will be the subject of filings for regulatory approval, that any drug candidates will receive marketing
approval from the U.S. Food and Drug Administration or equivalent regulatory authorities, or that drugs will be marketed successfully. Against the
background of these uncertainties readers should not rely on forward-looking statements. The company assumes no responsibility to update forwardlooking
statements or adapt them to future events or developments. This document does not constitute an offer or invitation to subscribe or
purchase any securities of Cytos Biotechnology AG.



For further information please contact:
Cytos Biotechnology AG, Wagistrasse 25, CH-8952 Schlieren
Claudine Blaser, PhD
Director Corporate Communications
phone: +41 44 733 47 20
e-Mail: claudine.blaser@cytos.com
Website: www.cytos.com
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
2. Prexige Study Shows Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
3. Lumiracoxib Study Showed Significantly Less Impact on Blood Pressure Than Ibuprofen in Osteoarthritis Patients with Controlled Hypertension
4. Amlodipine and Olmesartan Study Results Released;Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
5. Gilead Announces Presentation of Long-Term Data for Ambrisentan, a Potential Treatment for Patients With Pulmonary Arterial Hypertension
6. Hypertension Education Foundation Survey Results Announced At American Society For Hypertension Annual Meeting Suggests Improved Control Of High Blood Pressure, But Misconceptions Still Exist
7. New Data Highlights Potential of SPP100 (Tekturna) as Gold Standard Therapy in Treatment of Hypertension
8. Amlodipine and Olmesartan Study Results Released; Late Breaker Presented at American Society of Hypertension Twenty-Second Annual Scientific Meeting (ASH 2007)
9. King Pharmaceuticals Announces Plan to Present Results from Phase III Clinical Trial Evaluating ALTACE as Monotherapy and in Combination with Hydrochlorothiazide at the American Society of Hypertension Annual Meeting
10. Landmark Findings From ECLIPSE Program Show Improved Control of Perioperative Hypertension Reduces Risk of Death In Cardiac Surgery
11. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
Post Your Comments:
(Date:11/21/2014)... 2014  Edwards Lifesciences Corporation (NYSE: EW ... valves and hemodynamic monitoring, announced today that it will ... a strong launch of Edwards Lifesciences Foundation,s new charitable ... the global communities where its employees live and work. ... will exceed $8 million, including more than $7 million ...
(Date:11/21/2014)... /CNW Telbec/ - KLOX Technologies Inc. ("KLOX" or the ... Todd Martensen has been hired ... of Chief Commercial Officer, to oversee KLOX,s commercial launch ... for the treatment of chronic and other hard-to-heal wounds, ... in Europe . Mr. Martensen, a ...
(Date:11/21/2014)... GABLES, Fla. , Nov. 20, 2014   ... to become the first U.S. commercial producer of Molybdenum-99 ... a contract with INVAP to design its ... Fla. Mo-99 is the parent isotope of ... medicine procedures worldwide. In 2012, Congress passed legislation making ...
Breaking Medicine Technology:Edwards Lifesciences Increases Charitable Giving In 2014 To Support Launch Of Every Heartbeat Matters 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Coqui RadioPharmaceuticals Inks Deal With INVAP 2
... , LAIYANG, China, Nov. 16 /PRNewswire-Asia-FirstCall/ ... "Company"),a U.S. pharmaceutical company with its principal operations in the ... a conference,call at 9:00 a.m. Eastern Time on Wednesday, November ... fiscal year 2010. , Conference Call ...
... , STAMFORD, Conn., Nov. 13 ... will be releasing a free trial version of its Zargis ... conference, taking place this November 15-17 in Orlando. Zargis is ... the companion hardware -- the 3M Littmann Electronic Stethoscope Model ...
Cached Medicine Technology:Jiangbo Pharmaceuticals, Inc. Announces Conference Call to Discuss Results for the First Quarter of Fiscal Year 2010 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 2Zargis to Release Trial Version of Cardioscan while Exhibiting with 3M(TM) Littmann(R) at American Heart Association Conference 3
(Date:11/21/2014)... November 21, 2014 Body Well Therapy, a ... it accepts Spafinder massage gift cards and ... hotel massage in all service areas including throughout Florida and ... to go to the spa at all to redeem your ... of Body Well. "We may not be able to transport ...
(Date:11/21/2014)... The cost of diabetes care in the United States ... more than $322 billion annually, a new report shows. ... prediabetes care, which have risen 74 percent, and undiagnosed ... In 2012, excess medical costs and lost productivity ... American. That total includes $244 billion in medical costs ...
(Date:11/21/2014)... they,ve mapped the genome -- the genetic "blueprint" -- of ... it might help others with this very rare infection. ... , the tapeworm was removed from the brain of a ... so rare worldwide and completely unexpected in this country that ... pulled out from the brain," study lead author Hayley Bennett, ...
(Date:11/21/2014)... 21, 2014 MLF Biotech, Inc. has ... . Liv-Pro® Probiotics for Pets helps maintain digestive health ... a pet's intestinal flora after it experiences a period ... Liv-Pro Probiotics for Pets is a proprietary blend of ... seven live active bacteria strains that are safe and ...
(Date:11/21/2014)... 21, 2014 Saint Luke’s Mid ... The Guidelines®–Heart Failure Gold-Plus Quality Achievement Award for ... American Heart Association/American College of Cardiology Foundation in ... , Get With The Guidelines–Heart Failure is a ... the most up-to-date, research-based guidelines with the goal ...
Breaking Medicine News(10 mins):Health News:Body Well Mobile Massage Announces Acceptance of Spafinder Gift Cards for In Home Massage, Hotel Massage for Travelers 2Health News:Cost of Diabetes Care Keeps Climbing, Report Shows 2Health News:Ick! Tapeworm Infecting Man's Brain Yields Genetic Secrets 2Health News:MLF Biotech Introduces Liv-Pro Probiotics for Pets 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 2Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 3Health News:Saint Luke’s Mid America Heart Institute Awarded Get With The Guidelines Heart Failure Gold-Plus Quality Achievement Award 4
... March 7 Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ... webcast live during the Cowen & Company 28th ... 8:00 a.m. Eastern Time., The presentation will ... access the live presentation via the Web, please ...
... Affiliated Computer Services,Inc. (NYSE: ACS ) today ... to provide electronic health records and pharmacy,benefits management solutions. ... years,and a total value of $57 million if all ... will provide the state with several components,of ACS, electronic ...
... March 6 Nfocus Neuromedical, Inc.,announced today that ... StarFire Medical is a manufacturer of therapeutic implantable ... The assets acquired include products such as ... Silicone Balloon), also,known as the Endeavor Balloon Catheter, ...
... Webcast Scheduled for March 7, 2008 at 2:00 pm ... Ensign,Group, Inc. (Nasdaq: ENSG ), the parent company ... and assisted living,companies, today reported results for the fourth ... (Logo: http://www.newscom.com/cgi-bin/prnh/20071213/LATH168LOGO ), Highlights ...
... 6 QED International Associates, Inc.,administrator for the ... the HealthShares(TM) Exchange-Traded Funds, today announced,that effective at ... ISIS,Pharmaceuticals (Nasdaq: ISIS ) will replace Pharmion ... Index. Synta Pharmaceuticals Corp.,(Nasdaq: SNTA ) will ...
... A new study suggests that a type of acute ... one small molecule result in the over-activity of genes important ... myeloid leukemia (AML) and a gene mutation called NPM1, an ... The findings suggest new therapeutic targets for treating the disease ...
Cached Medicine News:Health News:Alexza's Corporate Presentation to be Webcast at the Cowen & Company 28th Annual Health Care Conference 2Health News:ACS Announces $57 Million Contract With Missouri HealthNet 2Health News:ACS Announces $57 Million Contract With Missouri HealthNet 3Health News:Nfocus Neuromedical Announces Acquisition of StarFire Medical 2Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 2Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 3Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 4Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 5Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 6Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 7Health News:The Ensign Group, Inc. Reports Fourth Quarter 2007 Earnings 8Health News:QED International Associates Announces Changes to the HealthShares(TM) Composite and HealthShares(TM) Cancer Indexes 2Health News:Low micro-RNA level linked to high gene activity in AML 2
... surgery, and the accompanying need for patient ... graft be developed. Grafts must not only ... available in varying sizes and configurations for ... long been the prosthetic of choice among ...
... GORE-TEX Vascular Grafts have met the challenges ... over 25 years. Recognized for exceptional performance ... of renowned surgeons worldwide. These grafts require ... of infection, and assure utmost thrombectomy safety. ...
... Vascular Grafts have met the challenges of ... 25 years. Recognized for exceptional performance and ... renowned surgeons worldwide. These grafts require no ... infection, and assure utmost thrombectomy safety. Gore ...
... Graft, the newest vascular graft offering from ... in vascular surgical products for more than ... kinking and compression problems that can ... provides all of the benefits of a ...
Medicine Products: